Innate Pharma
Oncology/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
The next generation of immunotherapy? Innate Pharma targets NK cells
Catherine Longworth
immunotherapy, Innate Pharma, Oncology, Sezary Syndrome
0 Comment
Innate Pharma gains rights to AZ’s recently approved leukaemia drug
Richard Staines
AstraZeneca, cancer, Innate Pharma, R&D
0 Comment
Future uncertain for Innate and BMS’ troubled lirilumab
Richard Staines
blood cancer, Bristol-Myers Squibb, cancer, head and neck cancer, Innate Pharma
0 Comment
Doubts over future of cancer immunotherapy
Bristol-Myers Squibb/ News/ R&D
Innate and BMS’ immunotherapy fails in phase 2 trial
Richard Staines
Bristol-Myers Squibb, cancer, cancer immunotherapy, Innate Pharma, R&D
0 Comment
French biotech developing cancer immunotherapy with BMS.
Bristol-Myers Squibb/ ESMO2016/ News/ R&D
Some good news for BMS with Opdivo + natural killer cell combination
Richard Staines
Bristol-Myers Squibb, cancer, immuno-oncology, Innate Pharma
0 Comment
But BMS dumps combination with Yervoy.